Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
Geode Capital Management LLC Acquires 20,203 Shares of Pacira Biosciences Inc (NASDAQ:PCRX)
09:20am, Sunday, 12'th Apr 2020
Geode Capital Management LLC grew its holdings in shares of Pacira Biosciences Inc (NASDAQ:PCRX) by 3.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutio
Genefit (GNFTF) Gets a Hold Rating from Stifel Nicolaus
05:40am, Sunday, 12'th Apr 2020
Stifel Nicolaus analyst Derek Archila reiterated a Hold rating on Genefit (GNFTF – Research Report) on April 9 and set
StartUPDATES: New developments from healthcare startups
05:50pm, Friday, 10'th Apr 2020
A roundup of new developments spotlighting startups this week including HealCo, PatientWing, as well as new research from Rock Health.
Should You Be Concerned About Pacira BioSciences, Inc.’s (NASDAQ:PCRX) Historical Volatility?
06:42pm, Wednesday, 08'th Apr 2020
If you own shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) then it's worth thinking about how it contributes to the...
Weekly Analysts' Ratings Changes for Pacira Biosciences (PCRX)
09:06am, Wednesday, 08'th Apr 2020
A number of firms have modified their ratings and price targets on shares of Pacira Biosciences (NASDAQ: PCRX) recently: 4/7/2020 – Pacira Biosciences is now covered by analysts at Northland Securit
Principia Biopharma (PRNB) Receives a Buy from Stifel Nicolaus
06:15am, Wednesday, 08'th Apr 2020
In a report released yesterday, Derek Archila from Stifel Nicolaus maintained a Buy rating on Principia Biopharma (PRNB), with a price target of $76.00.
Principia Biopharma (PRNB) Receives a Buy from Stifel Nicolaus
06:15am, Wednesday, 08'th Apr 2020
In a report released yesterday, Derek Archila from Stifel Nicolaus maintained a Buy rating on Principia Biopharma (PRNB – Research
Momenta Pharma (MNTA) Gets a Buy Rating from Stifel Nicolaus
10:40pm, Tuesday, 07'th Apr 2020
In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Momenta Pharma (MNTA). The company's shares closed last Tuesday
Momenta Pharma (MNTA) Gets a Buy Rating from Stifel Nicolaus
10:40pm, Tuesday, 07'th Apr 2020
In a report released today,
Derek Archila
from Stifel Nicolaus reiterated a
Buy
rating on Momenta Pharma (
MNTA
–
Research Report
). The company’s shares closed last Tuesday at $26.49.
According t
Hedge Funds Have Never Been More Bullish On Taubman Centers, Inc. (TCO)
09:01pm, Tuesday, 07'th Apr 2020
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted
Hedge Funds Have Never Been This Bullish On Hostess Brands, Inc. (TWNK)
09:01pm, Tuesday, 07'th Apr 2020
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Intra-Cellular Therapies Inc (ITCI): Are Hedge Funds Right About This Stock?
09:01pm, Tuesday, 07'th Apr 2020
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Should You Avoid Mueller Water Products, Inc. (MWA)?
09:01pm, Tuesday, 07'th Apr 2020
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Is Pacira Pharmaceuticals Inc (PCRX) Going to Burn These Hedge Funds?
09:00pm, Tuesday, 07'th Apr 2020
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Pacira Biosciences Inc (NASDAQ:PCRX) Shares Sold by AQR Capital Management LLC
08:24am, Tuesday, 07'th Apr 2020
AQR Capital Management LLC cut its stake in shares of Pacira Biosciences Inc (NASDAQ:PCRX) by 75.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and E
